Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from high prevalence tuberculosis states in Mexico

Mexico is one of the most important contributors of multidrug resistance tuberculosis (MDR-TB) in Latin-America, however little is known about the molecular characteristics of these strains. For this reason, the objective of this work was to determine the genotype and characterize polymorphisms in g...

Full description

Saved in:
Bibliographic Details
Published in:Infection, genetics and evolution genetics and evolution, 2017-11, Vol.55, p.384-391
Main Authors: Juarez-Eusebio, Dulce Maria, Munro-Rojas, Daniela, Muñiz-Salazar, Raquel, Laniado-Laborín, Rafael, Martinez-Guarneros, Jose Armando, Flores-López, Carlos A., Zenteno-Cuevas, Roberto
Format: Article
Language:English
Subjects:
Antitubercular Agents - pharmacology
Bacterial Proteins - genetics
Baja California
Cluster Analysis
Extensively Drug-Resistant Tuberculosis - epidemiology
Extensively Drug-Resistant Tuberculosis - microbiology
Genetic Variation
Genotype
Humans
Mexico - epidemiology
Microbial Sensitivity Tests
Minisatellite Repeats
Multidrug resistance
Multilocus Sequence Typing
Mutation
Mycobacterium tuberculosis - drug effects
Mycobacterium tuberculosis - genetics
Prevalence
Tuberculosis
Tuberculosis, Multidrug-Resistant - epidemiology
Tuberculosis, Multidrug-Resistant - microbiology
Veracruz
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mexico is one of the most important contributors of multidrug resistance tuberculosis (MDR-TB) in Latin-America, however little is known about the molecular characteristics of these strains. For this reason, the objective of this work was to determine the genotype and characterize polymorphisms in genes associated with resistance to rifampicin, isoniazid, and second-line drugs in isolates from two regions of Mexico with high prevalence of drug resistant tuberculosis. Clinical isolates from individuals with confirmed MDR-TB were genotyped using MIRU-VNTR 12 loci. To characterize the polymorphisms in genes associated with resistance to rifampicin, isoniazid and second-line drugs; rpoB, katG, inhA, rrs, eis, gyrA, gyrB and tlyA were sequenced. 22 (41%) of the 54 MDR-TB isolates recovered were from the state of Baja California, while 32 (59%) were from Veracruz. The results show the katGS315T mutation was observed in 20% (11/54) of the isolates, while rpoBS315L was present in 33% (18/54). rrs had three polymorphisms (T1239C, ntA1401C and ntA1401G), gyrB presented no modifications, whereas gyrA showed five (S95T, F60Y, A90V, S91P and P124A), eis two (G-10A and A431G) and tlyA one (insertion at codon 67). Only 20% (11/54) of isolates were confirmed as MDR-TB by sequencing, and no mutations at any of the genes sequenced were observed in 43% (23/54) of the strains. Two isolates were recognized with the proper set of mutations like pre-XDR and one was XDR-TB. Eighteen isolates were classified as orphans and the remaining thirty-six were distributed in fourteen lineages, the most frequent were S (11%), Haarlem (9%), Ghana (9%) and LAM (7%). Out of the fourteen clusters identified, seven included unknown genotypes and nine had lineages. This is one of the most detailed analyses of genotypic characteristics and mutations associated with drug resistance to first and second-line drugs in MDR-TB isolates from Mexico. An important genetic variability and significant discrepancy between phenotypic tests and polymorphisms was observed. Our results set the need to screen additional loci as well as implement a molecular epidemiological surveillance system of MDR-TB in the country. •Five novel polymorphisms in genes related to resistance against second line drugs were identified•An important genetic variability, as well as significant discrepancy between phenotypic tests and polymorphisms was observed•Only 20% of isolates were confirmed as MDR-TB by sequencing, however no muta
ISSN:1567-1348
1567-7257
DOI:10.1016/j.meegid.2016.09.012